Navigation Links
Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis

CHICAGO - Researchers suggest a short-term application of topical corticosteroids and maintenance with a less potent agent for patients// with intertriginous psoriasis (IP), according to a study published in the September issue of Archives of Dermatology, one of the JAMA/Archives journals.

Psoriasis is an inflammatory skin disease. In a subset of patients, psoriasis is located in the intertriginous areas, including the skin folds of the underarms, breasts, groin, buttocks and genitals, according to background information in the article. "Patients who exhibit intertriginous psoriasis often complain about intense itching, irritation from sweating and soreness. These symptoms may have devastating psychological and emotional consequences." Management of IP usually includes the application of topical corticosteroids, but those medications have adverse effects with long-term use.

In this study, Alexander Kreuter, M.D, from Ruhr University of Bochum, Germany, and colleagues conducted a randomized controlled trial that compared 1 percent pimecrolimus (a new anti-inflammatory drug), 0.005 percent calcipotriol, 0.1 percent betamethasone and the vehicle (a similarly appearing cream with no active drug) in the treatment of IP with a four-week treatment period and a six-week follow-up without therapy. A total of 80 adult patients with the clinical diagnosis of IP were included, 20 patients in each of the four treatment groups.

"After four weeks of treatment, the three active compounds and the vehicle resulted in a significant decrease in mean (average) M-PASI score [Modified Psoriasis Area and Severity Index] ( 86.4 percent for 0.1 percent betamethasone, 62.4 percent for 0.005 percent calcipotriol, 39.7 percent for 1 percent pimecrolimus and 21.1 percent for vehicle)," the researchers found. "The 0.1 percent betamethasone was significantly more effective than 1 percent pimecrolimus during the study period." The researchers report 25 percent of patients treated with pimecrolimus reported an increase in itching and burning shortly after application, however, most reactions lasted less than 30 minutes and resolved in a few days.

"In conclusion, this study indicated the efficacy of all three active compounds, 1 percent pimecrolimus, 0.1 percent betamethasone, and 0.005 percent calcipotriol (as well as the vehicle) in the treatment of IP. The 0.1 percent betamethasone was clearly more effective than 1 percent pimecrolimus, confirming that treatment with corticosteroids is still the most effective topical approach for psoriasis. However, their use in long-term management, particularly for the treatment of intertriginous areas, which are more prone to steroid adverse effects, is limited. To combine the rapid anti-inflammatory effects of a topical corticosteroid with the favorable long-term effects and safety profile of pimecrolimus or calcipotriol, short-term application of topical corticosteroids for acute disease followed by maintenance treatment with one of these agents seems to be a reasonable approach in the treatment of IP."
'"/>




Related medicine news :

1. Pneumonia Effectively Treated with Short-Term Antibiotic Course
2. Obese women Prone To Short-Term Disabilities
3. Topical Quinolone effective in controlling eardrum perforations
4. Corticosteroids Safe for Bones
5. Corticosteroids Safe for Bones
6. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
7. The Effectiveness Of Inhaled Corticosteroids Studied
8. The Effectiveness Of Inhaled Corticosteroids Studied
9. Systemic Corticosteroid Therapy can be used for treating all types of Infectious Mononucleosis
10. Inhaled Corticosteroids Reduce Death in Patients with COPD
11. High-dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... ... ... Elemental LED, a leading U.S. based engineering and technology company that ... honored with Architectural SSL Product Innovation Awards (PIA) for the most innovative ... LED, provides a wide variety of superior quality linear, task, and accent LED lighting ...
(Date:8/17/2017)... ... August 17, 2017 , ... In its just released 2018 ... and Harry Nelson. This is the third consecutive year that Hardiman and Mills have ... were both recognized for expertise in Health Care Law while Mills was recognized in ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, ... number of changes to the smartwatch market. As of June 2017, nearly nine percent ... the six months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast ...
(Date:8/17/2017)... ... 17, 2017 , ... Momkus McCluskey Roberts LLC recently announced it ... member of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... in matters of employment litigation, commercial litigation and business disputes. Her experience includes all ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Business Development Group, a Florida-based oncology business advisor to oncology practices, announced today ... the dollar amount of attributable savings from resolving critical clinical issues that would ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 Diplomat Pharmacy, Inc. ... Michigan residents. Naloxone ... Flint retail pharmacy, G-3320 Beecher Road. ... the Food and Drug Administration, is intended to block ... slowed breathing, and loss of consciousness. The medication is ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
Breaking Medicine Technology: